OmniAb, Inc. announced on April 21, 2025, the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. Concurrently, Director Sarah Boyce stepped down from her position.
Dr. Gotwals brings 30 years of biopharmaceutical experience, including roles in R&D, business development, and corporate development transactions, notably as Global Head of Business Development and Licensing at Novartis Institutes for BioMedical Research. Mr. Crouse offers over 20 years of experience in life sciences sales, marketing, and product development, currently serving as Senior Vice President, General Manager of the Analytical Solutions Division at Bio-Techne.
These appointments increase the number of directors to seven and are expected to provide valuable expertise in advancing OmniAb's strategic initiatives. The new directors' backgrounds in technology licensing and global tools and technology are anticipated to accelerate business growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.